Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation

Vascular calcification (VC) is associated with increased cardiovascular risks in patients with chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as empagliflozin, can improve cardiovascular and renal outcomes. We assessed the expression of Runt-related transcription facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chia-Wen, Lee, Chung-Jen, Hsieh, Yi-Jen, Hsu, Bang-Gee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298656/
https://www.ncbi.nlm.nih.gov/pubmed/37373164
http://dx.doi.org/10.3390/ijms241210016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298656/
https://www.ncbi.nlm.nih.gov/pubmed/37373164
http://dx.doi.org/10.3390/ijms241210016

Ejemplares similares